Latest Asx Company Filings News

Qualitas Real Estate Income Fund reported a robust FY25 with net assets soaring 44% to nearly $975 million and operating profit climbing 19.6%. The fund expanded its loan portfolio and successfully raised $295 million to fuel further growth.

Entertainment Rewards Ltd has expanded its loan facility by $3 million with Suzerain Investment Holdings, aiming to accelerate its Revenue Pivot Strategy and strengthen working capital.

Imperial Pacific Limited reported a 52% drop in profit for FY2025 but maintained its fully franked dividend, buoyed by robust performance from its associate London City Equities.

Health and Plant Protein Group Limited (HPP) reported a reduced net loss of $528,000 for FY2025, following the receipt of final proceeds from its US divestment. The Board signals plans to return capital and pursue new corporate opportunities.

Academies Australasia Group Limited reported a modest revenue rise and a dramatic 87% reduction in net loss for FY25, buoyed by improved cash flow and government visa policy changes affecting international student intake.

5E Advanced Materials has priced an $8.31 million public offering to fund its boron facility operations and development projects, reinforcing its position in specialty materials for clean energy and security.

Cannindah Resources announces the resignation of Managing Director Tom Pickett and appoints Cam Switzer as Interim CEO, signaling a new phase for the Mt Cannindah copper and gold project.

Peninsula Energy outlines a revised production roadmap for its Lance uranium project in Wyoming, addressing commissioning delays and legacy contract burdens while securing fresh capital to fuel growth amid strong US nuclear energy momentum.

RLF AgTech has secured a national supply agreement with Nutrien Ag Solutions, granting access to over 700 rural retail outlets across Australia. This partnership aims to boost RLF’s domestic presence and support sustainable farming practices.

Cue Energy Resources reported a 10% revenue increase to $54.8 million in FY2025, declaring a final dividend and advancing key development projects that underpin future growth.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.